Key result
In patients with acute decompensated heart failure, posttreatment LVEF was a significant predictor of all-cause mortality (HR 0.39), whereas baseline LVEF had no prognostic value.
Why the study?
Does posttreatment LVEF predict long-term prognosis better than baseline LVEF in patients with acute decompensated heart failure?
Cohort (n=428)
No
Does posttreatment LVEF predict long-term prognosis better than baseline LVEF in patients with acute decompensated heart failure?
Effect estimate: HR 0.39 (95% CI 0.22-0.67)
p-value: p=0.0008
In patients with acute decompensated heart failure, posttreatment LVEF at 6 months, but not baseline LVEF at admission, is a powerful predictor of long-term mortality and readmission.
Posttreatment LVEF may refine mortality risk stratification in acute decompensated HF; hypothesis-generating and requires prospective validation before practice change.
AIMS: The prognostic values of left ventricular ejection fraction (LVEF) during heart failure (HF) with acute decompensation or after optimal treatment have not been extensively studied. We hypothesized that posttreatment LVEF has superior predictive value for long-term prognosis than LVEF at admission does. METHODS AND RESULTS: In Protocol 1, 428 acute decompensated HF (ADHF) patients with LVEF ≤35% in a tertiary medical center were enrolled and followed for a mean period of 34.7 ± 10.8 months. The primary and secondary end points were all-cause mortality and HF readmission, respectively. In total, 86 deaths and 240 HF readmissions were recorded. The predictive values of baseline LVEF at admission and LVEF 6 months posttreatment were analyzed and compared. The posttreatment LVEFs were predictive for future events (P = 0.01 for all-cause mortality, P < 0.001 for HF readmission), but the baseline LVEFs were not. In Protocol 2, the outcomes of patients with improved LVEF (change of LVEF: ≥+10%), unchanged LVEF (change of LVEF: -10% to +10%), and reduced LVEF (change of LVEF: ≤-10%) were analyzed and compared. Improved LVEF occurred in 171 patients and was associated with a superior long-term prognosis among all groups (P = 0.02 for all-cause mortality, P < 0.001 for HF readmission). In Protocol 3, independent predictors of improved LVEF were analyzed, and baseline LV end-diastolic dimension (LVEDD) was identified as a powerful predictor in ADHF patients (P < 0.001). CONCLUSIONS: In patients with ADHF, posttreatment LVEF but not baseline LVEF had prognostic power. Improved LVEF was associated with superior long-term prognosis, and baseline LVEDD identified patients who were more likely to have improved LVEF. Therefore, baseline LVEF should not be considered a relevant prognosis factor in clinical practice for patients with ADHF.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2016) conducted a cohort in Acute Decompensated Heart Failure (n=428). Posttreatment LVEF vs. Baseline LVEF was evaluated on All-cause mortality (HR 0.39, 95% CI 0.22-0.67, p=0.0008). In patients with acute decompensated heart failure, posttreatment LVEF was a significant predictor of all-cause mortality (HR 0.39), whereas baseline LVEF had no prognostic value.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: